Abstract
Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Current Stem Cell Research & Therapy
Title:Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Volume: 10 Issue: 3
Author(s): Jingquan Liu, Bin Shi, Kai Shi and Hongze Zhang
Affiliation:
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Abstract: Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Export Options
About this article
Cite this article as:
Liu Jingquan, Shi Bin, Shi Kai and Zhang Hongze, Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases, Current Stem Cell Research & Therapy 2015; 10 (3) . https://dx.doi.org/10.2174/1574888X09666140820162716
DOI https://dx.doi.org/10.2174/1574888X09666140820162716 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Model with the GBDT for Colorectal Adenoma Risk Diagnosis
Current Bioinformatics Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Metabolism of Dietary Flavonoids in Liver Microsomes
Current Drug Metabolism Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Optimal Human Blood Sampling for Platelet Research
Current Angiogenesis (Discontinued) Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Nanoconstructs in Targeted Alpha-Therapy
Recent Patents on Nanomedicine ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science